Hormonal
A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.
For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.
When participants were stratified into eight groups by ABSI quartiles and RCII quartiles, the second ABSI quartile with high RCII showed the highest HR of 1.43 [95% CI:1.20–1.72], while the fourth ABSI quartile with high RCII had the greatest absolute CVD incidence.
Why this rating
Prospective cohort study with robust statistical adjustment for confounders.
Source
The effects of a body shape index and remnant cholesterol inflammatory index on incident cardiovascular diseases: insights from a nationwide cohort study
Linghao Xu et al. · Lipids in Health and Disease · 2026
DOI 10.1186/s12944-026-02893-7
More from this paper
- Elevated Remnant Cholesterol Inflammatory Index (RCII) is independently associated with a significantly higher risk of incident cardiovascular disease (CVD), including heart disease and stroke.Good
- RCII partially mediates the association between ABSI and incident CVD, with the mediation proportion increasing across higher ABSI quartiles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →